MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
|Articles|January 28, 2022
Demystifying Multiple Sclerosis Etiology: The Role of Epstein-Barr Virus
Author(s)NeurologyLive® Staff
Key Takeaways
- A novel longitudinal study by Ascherio et al. establishes a causal link between Epstein-Barr virus and multiple sclerosis.
- The discussion featured experts in neuroimmunology and virology, highlighting the study's implications for MS understanding and management.
An expert-led panel discuss the implications of recent findings that suggest a causative relationship between infection with Epstein-Barr virus and development of multiple sclerosis.
Advertisement
NeurologyLive, in partnership with the Consortium of Multiple Sclerosis Centers (CMSC), have brought together renowned experts in neuroimmunology and virology for an exclusive discussion of the implications of a recently published novel longitudinal study from Ascherio et al, the first of its kind to draw a
Experts featured in this NeurologyLive Peer Exchange special edition are Scott Newsome, DO; Alberto Ascherio, DrPH, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD.
Advertisement
Related to this article
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Here's some of what is coming soon to NeurologyLive® this week.
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
4
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
5